Humoral and cellular immune response to Plasmodium vivax VIR recombinant and synthetic antigens in individuals naturally exposed to P. vivax in the Republic of Korea

• Published in: Malaria journal Vol. 20; no. 1; pp. 1 - 288
• Main Authors: Lee, Sanghyun, Choi, Young-Ki, Goo, Youn-Kyoung
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 28-06-2021; BioMed Central; BMC
• Subjects: Analysis; Antibodies; Antigens; Cell activation; Cells; Cellular immune response; Chemical properties; Defence mechanisms; Demographic aspects; Development and progression; Diagnosis; Disease control; ELISA; Enzyme-linked immunosorbent assay; Genes; Granulocyte colony-stimulating factor; Health aspects; Human diseases; Humoral immune response; Immune response; Immune response (cell-mediated); Immune response (humoral); Immune system; Immunity; Immunoglobulin G; Immunoglobulin M; Interleukin 10; Interleukin 2; Interleukin 6; Laboratories; Leukocytes (mononuclear); Malaria; Molecular modelling; Parasites; Peptides; Plasmodium vivax; Proliferation; Proteins; Recombinants; Secretion; Synthetic peptides; Vaccines; Variant interspersed repeats protein; Vector-borne diseases; South Korea; New Zealand; Sweden; United States > US; Japan
• ISSN: 1475-2875; 1475-2875
• DOI: 10.1186/s12936-021-03810-2

Abstract
Background
Plasmodium vivax
proteins with variant interspersed repeats (VIR) are the key proteins used by the parasite to escape from the host immune system through the creation of antigenic variations. However, few studies have been done to elucidate their role as targets of immunity. Thus, this study evaluated the naturally-acquired immune response against VIR proteins in vivax malaria-infected individuals in the Republic of Korea (ROK).
Methods
Seven recombinant VIR proteins and two synthetic peptides previously studied in other countries that elicited a robust immune response were used to investigate the antibody and cellular immune response in 681
P. vivax
-infected people in ROK. The expression of IgM, IgG, and IgG subclasses against each VIR antigen or against PvMSP1-19 was analysed by ELISA. PvMSP1-19, known as a promising vaccine candidate of
P. vivax
, was used as the positive control for immune response assessment. Furthermore, the cellular immune response to VIR antigens was evaluated by in vitro proliferative assay, cellular activation assay, and cytokine detection in mononuclear cells of the
P. vivax
-infected population.
Results
IgM or IgG were detected in 52.4% of the population. Among all the VIR antigens, VIR25 elicited the highest humoral immune response in the whole population with IgG and IgM prevalence of 27.8% and 29.2%, respectively, while PvMSP1-19 elicited even higher prevalence (92%) of IgG in the population. As for the cellular immune response, VIR-C2, PvLP2, and PvMSP1-19 induced high cell activation and secretion of IL-2, IL-6, IL-10, and G-CSF in mononuclear cells from the
P. vivax
-infected population, comparable with results from PvMSP1-19. However, no significant proliferation response to these antigens was observed between the malaria-infected and healthy groups.
Conclusion
Moderate natural acquisition of antibody and cellular responses in
P. vivax
-infected Korean malaria patients presented here are similar to that in other countries. It is interesting that the immune response to VIR antigens is conserved among malaria parasites in different countries, considering that VIR genes are highly polymorphic. This thus warrants further studies to elucidate molecular mechanisms by which human elicit immune response to the malaria parasite VIR antigens.